Polymeric micelles for the pH-dependent controlled, continuous low dose release of paclitaxel.

Poly(ethylene glycol)-block-poly(aspartate-hydrazide) (PEG-p(Asp-Hyd)) was modified using either levulinic acid (LEV) or 4-acetyl benzoic acid (4AB) attached via hydrazone bonds. Paclitaxel (PTX) conjugated to the linkers formed PEG-p(Asp-Hyd-LEV-PTX) and PEG-p(Asp-Hyd-4AB-PTX). PEG-p(Asp-Hyd-LEV-PTX) and PEG-p(Asp-Hyd-4AB-PTX) assemble into unimodal polymeric micelles with diameters of 42 nm and 137 nm, respectively. PEG-p(Asp-Hyd-LEV-PTX) and PEG-p(Asp-Hyd-4AB-PTX) at a 1:1 and 1:5 molar ratio assemble into unimodal mixed polymeric micelles with diameters of 85 and 113 nm, respectively. PEG-p(Asp-Hyd-LEV-PTX) micelles release LEV-PTX faster at pH 5.0 than at pH 7.4 over 24 h. At pH 7.4 mixed polymeric micelles at 1:5 ratio show no difference in LEV-PTX release from PEG-p(Asp-Hyd-LEV-PTX) micelles. Mixed polymeric micelles at 1:5 molar ratio gradually release LEV-PTX at pH 5.0, with no release of 4AB-PTX. PEG-p(Asp-Hyd-LEV-PTX) micelles and mixed polymeric micelles exert comparable cytotoxicity against SK-OV-3 and MCF-7 cancer cell lines. In summary, mixed polymeric micelles based on PEG-p(Asp-Hyd-LEV-PTX) and PEG-p(Asp-Hyd-4AB-PTX) offer prospects for pH-dependent release of PTX, offering a novel prodrug strategy for adjusting its pharmacokinetic and pharmacodynamic properties for cancer therapy. If successful this delivery system offers an alternative new mode of delivery for paclitaxel with a new scope for its efficacy along with a minimal synthetic framework needed to accomplish this.

[1]  R. Kerbel,et al.  Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL–Based Paclitaxel , 2006, Clinical Cancer Research.

[2]  N. F. Magri,et al.  Preparation and biological activity of taxol acetates. , 1984, Biochemical and biophysical research communications.

[3]  Yokoyama Masayuki,et al.  Polymer micelles as novel drug carrier: Adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer , 1990 .

[4]  Kazunori Kataoka,et al.  Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery. , 2005, Molecular bioSystems.

[5]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[6]  N. Nishiyama,et al.  In vivo antitumor activity of the folate-conjugated pH-sensitive polymeric micelle selectively releasing adriamycin in the intracellular acidic compartments. , 2007, Bioconjugate chemistry.

[7]  E. Rowinsky,et al.  Paclitaxel in cancer treatment , 1995 .

[8]  V. Stella,et al.  Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. , 1991, American journal of hospital pharmacy.

[9]  G. Kwon,et al.  Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[10]  W. Lorenz,et al.  Histamine release in dogs by Cremophor El® and its derivatives: Oxethylated oleic acid is the most effective constituent , 1977, Agents and Actions.

[11]  Atsushi Harada,et al.  Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. , 2003, Angewandte Chemie.

[12]  Y. Matsumura.  Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. , 2008, Advanced drug delivery reviews.

[13]  Patrick Soon-Shiong,et al.  Protein nanoparticles as drug carriers in clinical medicine. , 2008, Advanced drug delivery reviews.

[14]  J. Watkins,et al.  Suspected anaphylactic reaction to Cremophor EL. , 1980, British medical journal.

[15]  Kinam Park,et al.  Hydrotropic polymeric micelles for enhanced paclitaxel solubility: in vitro and in vivo characterization. , 2007, Biomacromolecules.

[16]  B. Leyland-Jones,et al.  Hypersensitivity reactions from taxol. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[18]  M. R. Mejillano,et al.  Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. , 1992, Journal of medicinal chemistry.

[19]  T. Okano,et al.  Preparation of micelle-forming polymer-drug conjugates. , 1992, Bioconjugate chemistry.

[20]  T. Fojo,et al.  Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  M. Allwood,et al.  The extraction of diethylhexylphthalate (DEHP) from polyvinyl chloride components of intravenous infusion containers and administration sets by paclitaxel injection , 1996 .

[22]  T. Okano,et al.  Improved synthesis of adriamycin-conjugated poly (ethylene oxide)-poly (aspartic acid) block copolymer and formation of unimodal micellar structure with controlled amount of physically entrapped adriamycin , 1994 .

[23]  T. Okano,et al.  Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. , 1990, Cancer research.

[24]  A. Sparreboom,et al.  Taxane-Mediated Antiangiogenesis in Vitro , 2004, Cancer Research.